Sanofi’s Acquisition of Dynavax Nears Final Approval

A key regulatory obstacle has been cleared for Sanofi’s planned $2.2 billion purchase of Dynavax Technologies, moving the major pharmaceutical deal closer to completion. The transaction, aimed at bolstering the French giant’s standing in the adult vaccine market, recently received a crucial green light from German investment control authorities.

Sanofi first announced its intention to acquire Dynavax in late 2025. The agreement involves a cash payment of $15.50 per share, a figure that represented a significant premium to the market price at the time of the deal’s announcement. With the latest regulatory approval secured on January 29, 2026, the parties are targeting a final closing within the first quarter of 2026.

Market sentiment Read more...